ZTlido FDA Approval History
FDA Approved: Yes (First approved February 28, 2018)
Brand name: ZTlido
Generic name: lidocaine
Dosage form: Patch
Previous Name: Ztilido
Company: Scilex Pharmaceuticals, Inc.
Treatment for: Postherpetic Neuralgia
ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia.
Development timeline for ZTlido
| Date | Article |
|---|
| Feb 28, 2018 | Approval Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain |
| Sep 12, 2017 | FDA Acknowledges Receipt of Sorrento Therapeutics Inc, NDA for ZTlido |
| Aug 29, 2017 | Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch |
| Sep 16, 2015 | FDA Accepts Scilex Pharmaceuticals' NDA Filing for ZTlido |
| May 15, 2014 | Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido |
| Mar 24, 2014 | Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
